More on Amarin Q1 results


Amarin Corp (AMRN) Vascepa sales: $11M (+378.3%); gross margin: 61.3% (+36.2%); operating loss: ($25.6M) (+57.4%); loss/share: ($0.15) (+65.1%); quick assets (ex-A/R): $164.9M (-14.3%).

Formulary coverage now >200M lives including >100M Tier 2 coverage. Estimated Vascepa prescriptions by Symphony Health Solutions and IMS Health were 93K and 78K, respectively.

$100M will be required to finish the REDUCE-IT clinical trial. The company states it may be difficult to complete it without the expected revenues from the previously anticipated ANCHOR indication. Without modification or termination, REDUCE-IT will not be completed until 2017.

$11M in Vascepa sales was based on sales to distributors not the resale of the product to fill prescriptions, which was the method it used until it gained a reliable estimate of returns. Under its old method, Vascepa sales would have been $10M.

From other sites
Comments (4)
  • ralphey
    , contributor
    Comments (380) | Send Message
     
    As I have been saying - best product in class - period - despite the shenanigans by the FDA, GSK and others to suppress vascepa - the cream always does rise to the top ...and then VAscepa takes care of it
    9 May 2014, 09:21 AM Reply Like
  • TincoMonkey
    , contributor
    Comments (107) | Send Message
     
    "Without modification or termination, REDUCE-IT will not be completed until 2017."

     

    Surely a termination would would also mean REDUCE-IT will not be completed until 2017 or any other date. Are we having a bad language day here?
    9 May 2014, 10:17 AM Reply Like
  • 2puttwo
    , contributor
    Comments (655) | Send Message
     
    Let's wait till the next quarter to see how the reinforcement sales team does. I think Monday is a great day to gamble on Amarin. "But it is the end of the beginning" WC, I think this is the bottom. GL
    9 May 2014, 10:08 PM Reply Like
  • ralphey
    , contributor
    Comments (380) | Send Message
     
    The new guidelines indicate non -hdl levels are MORE important than LDL-C levels .
    Vascepa lowers non -hdl by 18% !! THis opens many doors - it will be added onto many statins - ever wonder y KOWA has joined the effort ? They have a statin LIvalo

     

    I wish Pfizer would have picked it up and comboed with lipitor ...... but a livalo vascepa combo is going to be groundbreaking ! Statins will slip to the way side as everyone realizes that a statin omega 3 combo is superior
    10 May 2014, 09:35 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs